Tuesday, July 8, 2014

Top 10 Safest Stocks To Buy Right Now

The New York Times called it a "moment of reckoning." Widely followed commodities trader Dennis Gartman in a note to his clients wrote that he's "never...ever...EVER" seen anything quite like it.

The references, of course, are to March 15's collapse in the price of gold, the largest single-day percentage drop in 30 years, capping a two-day decline of 13%.

The selling was triggered in part by worries that Cyprus and possibly other European nations might have to dump their gold holdings to raise funds or satisfy bailout requirements. Also, after acting as a commodities tailwind for much of the past two years, the Fed's quantitative easing program looks to be winding down, which would relax inflationary pressure.

Suddenly, the "safest" investment no longer seemed so safe. In fact, there's a good chance that gold's 12-year streak of uninterrupted gains will come to an end this year.

Top 10 Consumer Stocks To Own Right Now: PerkinElmer Inc.(PKI)

PerkinElmer, Inc. provides technology, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates in two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, as well as accelerate the discovery and development of critical new therapies. This segment provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. It also provides a suite of solutions, including instrumentation for automation and detection solutions, in vitro and in vivo imaging and analysis hardware and software, and a portfolio of consumable products, such as drug discovery and research reagents that enable researchers to enhance the drug discovery process. The Environmental Health segment offers t echnologies and applications to facilitate the creation of safer food and consumer products, secure surroundings, and efficient energy resources. This segment provides analytical technologies that address the quality of environment, sustainable energy development, and ensure safer food and consumer products; analytical instrumentation for the industrial market, which includes the semiconductor, chemical, petrochemical, lubricant, construction, office equipment, and quality assurance industries; and laboratory services. The company markets its products and services directly through its own sales forces and distributors for customers, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:
  • [By David Goodboy]

    In other bullish news, TrovaGene entered into a material agreement with multibillion-dollar diagnostics technology leader PerkinElmer (NYSE: PKI) to jointly develop a test to determine a person's risk of developing hepatocellular carcinoma (HCC). The terms have not been disclosed, but PerkinElmer will make milestone payments to TrovaGene. 

  • [By Rich Smith]

    The Department of Defense awarded a dozen separate contracts Thursday, worth more than $225 million in aggregate. Notable winners (among publicly traded companies) included:

  • [By Ben Levisohn]

    The market erased early-morning losses after strong service-sector data confirmed that the US economy has managed to keep-on keeping-on, no matter what has happened overseas. PerkinElmer (PKI), Boeing (BA), and Keurig Green Mountain (GMCR) have gained, while Plug Power (PLUG) and Tyson Foods (TSN) have dropped.

  • [By Daniel Lauchheimer]

    Let us contrast this with TROV's progress. TROV has secured two critical partnerships -- with Illumina (ILMN), and PerkinElmer (PKI). Company filings on the ILMN deal don't provide much detail, but the filings with the PKI deal detail how PKI wants to use TROV's science to develop a new t assay to detect the presence of hepatocelluar carcinoma (HCC). While these two partnerships do not guarantee approval in any way, they do provide a solid validation for TROV's technology.

Top 10 Safest Stocks To Buy Right Now: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:
  • [By Anders Bylund]

    No. 1 with a bullet
    Nobody, but nobody, is beating Clovis Oncology (NASDAQ: CLVS  ) right now. The cancer-focused biotech company got the party started with a fine earnings report in February, which helped push the stock 15% higher overnight. But that's nothing next to the 136% one-day pop Clovis experienced after releasing positive data from early-stage studies on two types of cancer-busting drugs.

Top 10 Safest Stocks To Buy Right Now: Granite Construction Inc (GVA)

Granite Construction Incorporated (Granite), incorporated on January 24, 1990, is a diversified heavy civil contractors and construction materials producers in the United States. The Company operates in four segments: Construction, Large Project Construction, Construction Materials and Real Estate. The Company operates nationwide, serving both public and private sector clients. Within the public sector, it primarily concentrates on heavy-civil infrastructure projects, including the construction of roads, highways, mass transit facilities, airport infrastructure, bridges, dams and other infrastructure related projects. Within the private sector, it performs site preparation and infrastructure services for residential development, commercial and industrial buildings, and other facilities. The Company owns and leases substantial aggregate reserves and own a number of construction materials processing plants. It also has contractor-owned heavy construction equipment fleets in the United States. In December 2012, it purchased 100% interest of Kenny Construction Company (Kenny).


Revenue from its Construction segment was approximately 47% of its total revenue during the year ended December 31, 2012. Revenue from its Construction segment is derived from both public and private sector clients. The Construction segment performs various heavy civil construction projects with a large portion of the work focused on new construction and improvement of streets, roads, highways, bridges, site work and other infrastructure projects. These are typically bid-build projects completed within two years.

Large Project Construction

Revenue from its Large Project Construction segment was 41.4% of its total revenue in 2012. The Large Project Construction segment focuses on large, complex infrastructure projects, which typically have a longer duration than its Construction segment work. These projects include major highways, mass transit facilities, bridges, tunn! els, waterway locks and dams, pipelines, canals and airport infrastructure. This segment primarily includes bid-build, design-build and construction management/general contractor contracts. It participates in joint ventures with other construction companies mainly on projects in its Large Project Construction segment. Joint ventures are typically used for large, technically complex projects, including design/build projects, where it is desirable to share risk and resources. Joint venture partners typically provide independently prepared estimates, shared financing and equipment and often bring local knowledge and expertise.

The Company also utilizes the design/build and construction management/general contract methods of project delivery. Under the construction management/general contract method of delivery, it contracts with owners to manage the design phase of the contract with the understanding that it will negotiate a contract on the construction phase when the design nears completion. Revenue from design/build and construction management/general contract projects represented 74.5% of Large Project Construction revenue in 2012.

Construction Materials

Revenue from its Construction Materials segment was 11.1% of its total revenue in 2012. The Construction Materials segment mines and processes aggregates and operates plants that produce construction materials for internal use and for sale to third parties. It has aggregate reserves that it has acquired by ownership in fee or through long-term leases. Aggregate products used in its construction projects represented approximately 42.7% of its tons sold during 2012.

Real Estate

Granite Land Company (GLC) is an investor in a diversified portfolio of land assets and provides real estate services for other Granite operations. GLC�� investment portfolio consists of residential, as well as retail and office site development projects for sale to home and commercial property developers. The range! of its i! nvolvement in an individual project may vary from passive investment to management of land use rights, development, construction, leasing and eventual sale of the project. Generally, GLC has teamed with partners who have local knowledge and expertise in the development of each property. GLC�� investments are located in Washington, California and Texas. Revenue from GLC was 0.2% of its total revenue in 2012.

Advisors' Opinion:
  • [By Louis Navellier]

    If we look at the sector using Portfolio Grader, we see that many of the big names in the group like Flour (FLR), Granite Construction (GVA) and KBR incorporated (KBR) are rated ��ell.��The anticipated spending for both government and private industry simply hasn�� materialized, and the companies are not seeing revenue or profit growth.

Top 10 Safest Stocks To Buy Right Now: Amsurg Corp.(AMSG)

AmSurg Corp., through its wholly owned subsidiaries, engages in the development, acquisition, and operation of ambulatory surgery centers in partnership with physicians in the United States. The company?s surgery centers perform colonoscopy and other endoscopy procedures in the area of gastroenterology; cataracts and retinal laser surgery in the area of ophthalmology; and knee and shoulder arthroscopy and carpal tunnel repair in the area of orthopedics. As of December 31, 2010, it owned interest in 204 surgery centers in 33 states and the District of Columbia, including 140 centers performed gastrointestinal endoscopy procedures, 37 centers performed ophthalmology surgery procedures, 19 centers were multiple specialties, and 8 centers performed orthopaedic procedures. AmSurg Corp. markets its surgery centers directly to patients; and referring physicians and third-party payors, such as health maintenance organizations, preferred provider organizations, other managed care o rganizations, and employers. The company was founded in 1992 and is headquartered in Nashville, Tennessee.

Advisors' Opinion:
  • [By Tom Lydon]

    Top holdings based on the index include Acadia Healthcare Companies (ACHC), Amsurg Corporation (AMSG), Brookdale Senior Living (BKD), Clarcor (CLC) and Community Health Systems (CYH).

  • [By Seth Jayson]

    AmSurg (Nasdaq: AMSG  ) is expected to report Q1 earnings on April 24. Here's what Wall Street wants to see:

    The 10-second takeaway
    Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AmSurg's revenues will grow 13.6% and EPS will grow 4.0%.

Top 10 Safest Stocks To Buy Right Now: Mastercard Incorporated(MA)

MasterCard Incorporated, together with its subsidiaries, provides transaction processing and related services to customers principally in support of their credit, deposit access, electronic cash and automated teller machine payment card programs, and travelers? cheque programs. Its payment solutions include payment programs, marketing, product development, technology, processing, and consulting and information services. The company provides transaction processing services comprising transaction switching, which include authorization, clearing, and settlement; connectivity services, such as network access, equipment, and the transmission of authorization and settlement messages; and other payment-related services consisting of products used to prevent or detect fraudulent transactions, cardholder services, professional consulting and research services, compliance and penalty, account and transaction enhancement services, holograms, and publication services. MasterCard Incor porated manages and licenses payment card brands, including MasterCard, MasterCard Electronic, Maestro, and Cirrus. The company?s payment programs, which are facilitated through its brands, include consumer credit, debit and prepaid programs, commercial payment solutions, and contactless payment solutions. It serves approximately 22,000 financial institutions. The company was founded in 1966 and is headquartered in Purchase, New York.

Advisors' Opinion:
  • [By Dan Caplinger]

    The scope of Visa's business is truly astonishing. In the first quarter, Visa topped the $1.6 trillion mark in total dollar volume, staying ahead of the surging MasterCard (NYSE: MA  ) with its faster 12% dollar-volume growth rate bringing it to almost $950 billion. That keeps the pair comfortably ahead of American Express (NYSE: AXP  ) , which gets a big portion of its revenue not from payment processing but from taking on credit risk associated with actually issuing its own cards. Visa had 2.1 billion cards with its logo as of the end of 2012, beating out its rivals on that score as well.

  • [By Ben Levisohn]

    Two credit-card companies, two different responses to their earnings. While disappointed investors have sold off shares of Visa (V), MasterCard (MA) is relatively unchanged.

Top 10 Safest Stocks To Buy Right Now: Liberty Media Corp (LMCA)

Liberty Media Corporation, formerly Liberty Spinco, Inc., incorporated on August 10, 2012, focuses on the media, communications and entertainment industries through its ownership of interests in subsidiaries and other companies. Its businesses and assets include consolidated subsidiaries, Atlanta National League Baseball Club, Inc. and TruePosition, Inc., its equity affiliates Sirius XM Radio Inc. and Live Nation Entertainment, Inc. and minority investments in public companies such as Barnes & Noble, Inc., Time Warner Inc., Time Warner Cable, Inc., Viacom Inc. and Sprint Nextel Corporation. On January 11, 2013, Liberty Media Corporation and Starz announced the completion of the spin-off of Liberty from Starz. In connection with the spin-off, Liberty changed its name from Liberty Spinco, Inc. to Liberty Media Corporation. In January 2013, the Company announced that it held approximately 50.7% interest of Sirius XM Radio Inc. In May 2013, Liberty Media Corp acquired a 27.38% stake in Charter Communications Inc.

Atlanta National League Baseball Club, Inc., or ANLBC, a wholly owned subsidiary, owns and operates the Atlanta Braves Major League Baseball (MLB) franchise and five minor league baseball clubs (the Gwinnett Braves, the Mississippi Braves, the Rome Braves, the Danville Braves and the GCL Braves). TruePosition is a wholly owned subsidiary that develops and markets technology for locating wireless phones and other wireless devices enabling wireless carriers, application providers and other enterprises to provide E-911 services domestically and other location-based services to mobile users both domestically and worldwide. Sirius XM Radio Inc. (Sirius) broadcasts its music, sports, entertainment, comedy, talk, news, traffic and weather channels in the United States on a subscription fee basis through its two satellite radio systems. Subscribers can also receive certain of its music and other channels over the Internet, including through applications for mobile devices.

Sir! ius XM Radio Inc. satellite radios are primarily distributed through automakers (OEMs), retail locations nationwide, and through its Website. Sirius offers a dynamic programming lineup of commercial-free music, sports, entertainment, talk, news, traffic and weather. The channel line-ups for its services vary in certain respects and are available at siriusxm.com. Sirius offers a selection of music genres, ranging from rock, pop and hip-hop to country, dance, jazz, Latin and classical. Within each genre it offers a range of formats, styles and recordings. Sirius offers a range of national, international and financial news, including news from BBC World Service News, Bloomberg Radio, CNBC, CNN, FOX News, HLN, MSNBC, NPR and World Radio Network. Barnes & Noble, Inc., is a content, commerce and technology company providing customers easy and convenient access to books, magazines, newspapers and other content across its multi-channel distribution platform. As of April 28, 2012, Barnes & Noble operated 1,338 bookstores in 50 states, including 647 bookstores on college campuses, operates one of the Internet's e-Commerce sites and develops digital content products and software.

Advisors' Opinion:
  • [By Hibah Yousuf]

    Media mogul John Malone's Liberty Media (LMCA) is the largest shareholder in Charter and Malone has been a loud supporter of more consolidation in the cable industry, which is facing rising costs in programming.

Top 10 Safest Stocks To Buy Right Now: Roche Holding AG (RHHBY)

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.

During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.

In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.


Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.


Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.

Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.

Advisors' Opinion:
  • [By Maxx Chatsko]

    Anytime a megablockbuster nears the end of its IP-protected life, plenty of companies will emerge to get a piece of the pie. In this case,�Roche� (NASDAQOTH: RHHBY  ) has two megablockbusters with a combined $13.5 billion in 2012 sales coming off patent in the next several years. That is bad news for the innovator, but opens a big opportunity for the various companies targeting biosimilars. In fact, a total of 19 trials are under way to develop generic versions of Rituxan and Herceptin. In the following video, Fool contributor Maxx Chatsko tells investors which companies to keep an eye on in the race to unseat Roche.

No comments:

Post a Comment